In ATC with higher PD-L1/TMB, the effect of immune checkpoint inhibitors is still low (ORR <10%) (36,37), as the slow response to treatment (>8 weeks) cannot keep pace with the aggressive tumor growth. Here, CD274 is linked to neoplasm.